10-Q quarterly report · filed Nov 5, 2026

Guardant Health, Inc. (GH) Q3 2026 10-Q Quarterly Report

Short answer

Guardant Health, Inc. (GH) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $361M (up 36.1% year over year) with net income of −$124M.

Q3 2026 key financials · XBRL

Revenue
$361M
+36.1% YoY · +7.8% QoQ
Net income
−$124M
−34.1% YoY · −3.5% QoQ
Operating margin
-36.8%
EPS (diluted)
−$0.92
−22.7% YoY · −1.1% QoQ

Source: XBRL data from the Guardant Health, Inc. (GH) Q3 2026 10-Q on SEC EDGAR. USD.

Guardant Health, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $361.0M, up 36% YoY from $265.2M
  • Operating loss $132.8M vs $99.0M YoY, operating margin (36.8%) vs (37.3%)
  • Best segment Screening: $67.6M, up 180% YoY; worst growth Biopharma and data: $59.0M, up 8%
  • Cash, equivalents and restricted cash $1.1B; nine-month operating cash outflow $147.1M vs $158.4M
  • Outlook: additional operating losses expected; liquidity sufficient for more than 12 months, reimbursement variability remains a headwind

Risk Factors

  • New cybersecurity risk triggered by unauthorized portal access, with certain patient records potentially accessed
  • AI-enabled attacks increasing speed, scale and sophistication of exploitation
  • Regulatory exposure from compromised patient data, including investigations, enforcement actions and penalties
  • Operational disruption risk across testing, reporting, billing and reimbursement systems
  • Third-party service-provider vulnerabilities potentially compromising Guardant information systems

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Guardant Health, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.